Lifecore Biomedical

Yahoo Finance • 19 days ago

Here’s the Analysis of LifeCore’s (LFCR) Growth Potential

Greenhaven Road Capital, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund returned approximately -9%, bringing the YTD returns to... Full story

Yahoo Finance • 22 days ago

Lifecore outlines $74M–$76M revenue target for transition period while advancing commercial wins and margin expansion

Earnings Call Insights: Lifecore Biomedical, Inc. (LFCR) Q3 2025 MANAGEMENT VIEW * CEO Paul Josephs highlighted, "Lifecore is a differentiated injectable CDMO with a strong foundation in high-grade hyaluronic acid that has served as ou... Full story

Yahoo Finance • 30 days ago

Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025

CHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial result... Full story

Yahoo Finance • 30 days ago

Here’s Why Lifecore Biomedical Inc (LFCR) Declined 22% at the End of Q3

Laughing Water Capital, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the third quarter of 2025, Laughing Water Capital declined approximately -1% net of... Full story

Yahoo Finance • last month

Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company

Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product Represents Second Agreement Signed with Same Major Multinational Organization in Recent Months Separa... Full story

Yahoo Finance • last month

Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market

CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and PolyPeptide Laboratories, I... Full story

Yahoo Finance • 2 months ago

Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events

CHASKA, Minn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at... Full story

Yahoo Finance • 2 months ago

Stocks Supported by AI Spending Boom

The S&P 500 Index ($SPX) (SPY) today is up +0.40%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.84%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.07%.  December E-mini S&P futures (ESZ25) are up +0.37%, and December E-mini Nas... Full story

Yahoo Finance • 2 months ago

Stocks Climb on Rampant AI Optimism

The S&P 500 Index ($SPX) (SPY) today is up +0.29%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.45%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.18%.  December E-mini S&P futures (ESZ25) are up +0.27%, and December E-mini Nas... Full story

Yahoo Finance • 2 months ago

LIFECORE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating LifeCore Biomedical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In LifeCore (LFCR) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in LifeCore between October 7, 2... Full story

Yahoo Finance • 2 months ago

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CHASKA, Minn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on September 22, 2025, the Life... Full story

Yahoo Finance • 3 months ago

Lifecore Biomedical to Participate at 24th Annual Contract Pharma Contracting and Outsourcing Conference

CHASKA, Minn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate a... Full story

Yahoo Finance • 3 months ago

Lifecore granted Sector Weight rating at KeyBanc on growth trajectory

[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images KeyBanc Capital Markets has initiated the coverage of Lifecore Biomedical (NASDAQ:LFCR [https://seekingalpha.com/symbol/LFCR]) with a Sector Weight recommendation, notin... Full story

Yahoo Finance • 3 months ago

Lifecore Biomedical to Participate in Upcoming Investor Conferences

CHASKA, Minn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate i... Full story

Yahoo Finance • 3 months ago

Does LifeCore (LFCR) Have a High Expected Value?

Greenhaven Road Capital, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. A copy of the letter can be downloaded here. In the second quarter, the fund returned... Full story

Yahoo Finance • 4 months ago

LIFECORE ALERT: Bragar Eagel & Squire, P.C. is Investigating LifeCore Biomedical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In LifeCore (LFCR) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in LifeCore between October 7, 2... Full story

Yahoo Finance • 4 months ago

Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

-- Recorded $128.9 Million in Fiscal 2025 Revenue, Meeting Full-Year Guidance; Maintains Commitment to Mid-Term Outlook -- -- Nine New Programs Signed with New Customers During Fiscal 2025, Reflecting Growth into Modalities Beyond the Co... Full story

Yahoo Finance • 4 months ago

Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August 7, 2025

CHASKA, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial result... Full story

Yahoo Finance • 4 months ago

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHASKA, Minn., July 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on July 11, 2025, the Lifecore c... Full story

Yahoo Finance • 5 months ago

Lifecore signs 10-year manufacturing deal with key ophthalmic client

CHASKA, Minn. - Lifecore Biomedical, Inc. (NASDAQ: LFCR), a $247 million market cap company with annual revenues of $130 million, has secured a new 10-year commercial manufacturing and supply agreement with an existing customer for an opht... Full story